Yu Tang
Peking Union Medical College
55 Papers
79 Citations
Yu Tang is an academic researcher from Peking Union Medical College. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 8, co-authored 44 publications.
Chat about Author
Papers
Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial.
Shu Lian Wang,Hui Fang,Yong Wen Song,Wei Hu Wang,Chen Hu,Yue Ping Liu,Jing Jin,X.F. Liu,Zi hao Yu,Hua Ren,Ning Li,Ning Ning Lu,Yu Tang,Yuan Tang,Shu Nan Qi,Guangyi Sun,Ran Peng,Shuai Li,Bo Chen,Yong Yang,Ye Xiong Li +20 more
TL;DR: Postmastectomy hypofractionated radiotherapy was non-inferior to and had similar toxicities to conventional fractionated radi therapy in patients with high-risk breast cancer.
347
Fully automatic and robust segmentation of the clinical target volume for radiotherapy of breast cancer using big data and deep learning.
TL;DR: The proposed DD-ResNet method could segment the CTV accurately with acceptable time consumption and could improve the consistency of target delineation and streamline radiotherapy workflows.
151
CNN-Based Quality Assurance for Automatic Segmentation of Breast Cancer in Radiotherapy.
TL;DR: An automatic quality assurance (QA) method for automatic segmentation using convolutional neural networks (CNNs) that could predict the segmentation quality automatically and can provide useful information for physicians regarding further verification and revision of automatic contours.
Radiation-Induced Lymphopenia Predicts Poorer Prognosis in Patients With Breast Cancer: A Post Hoc Analysis of a Randomized Controlled Trial of Postmastectomy Hypofractionated Radiation Therapy.
Guangyi Sun,Shulian Wang,Yongwen Song,Jing Jin,Weihu Wang,Yueping Liu,Hua Ren,Hui Fang,Yu Tang,Xu-Ran Zhao,Y.W. Song,Zihao Yu,Xin-Fan Liu,Yexiong Li +13 more
TL;DR: The risk of RIL in breast cancer patients is lower with HFRT than with CFRT, and a low nadir-PLC/pre-P LC ratio may predict poor prognosis.
50
Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a Phase II clinical trial.
Jun Liang,Mingyan E,Gang Wu,Lujun Zhao,Xia Li,Xia Xiu,Ning Li,Bo Chen,Zhouguang Hui,Jima Lv,Hui Fang,Yu Tang,Nan Bi,Wenqing Wang,Yirui Zhai,Tao Li,Dongfu Chen,Shuangmei Zou,Ning Lu,Rolando Perez-Rodríguez,Junqi Zheng,Luhua Wang +21 more
TL;DR: This study shows that nimotuzumab combined with radiotherapy was well tolerated in patients with esophageal cancer, and OS was higher after combined therapy than after historical control radiotherapy alone.